Summary
Transduction of therapeutic transgenes using multiply attenuated viral vectors is considered an essential technology for gene therapy scenarios. While first-generation viral transduction systems were engineered for constitutive expression of a single therapeutic transgene, most advanced viral gene-transfer technologies enable regulated expression of several transgenes. Efficient transfer of numerous transgenes enables co-expression of therapeutic transgenes along with marker or selection determinants, production of multi-subunit protein complexes, or combinatorial expression of a particular set of genes to treat multigenic disorders. Likewise, adjustable transcription control is fundamental to adapt therapeutic protein production to the changing daily dosing regimes of a patient, to titrate expression of protein pharmaceuticals into the therapeutic window, and to reverse dosing upon completion of the therapy. Also, conditional transcription dosing has been successfully used for production of difficult-to-express protein therapeutics in biopharmaceutical manufacturing and for sophisticated gene-function analysis in basic research programs. By way of example, we provide detailed design (auto-regulated and binary dual-regulated expression configurations), production (generation, purification, and quality control of transgenic adenovirus particles), and handling (transduction) protocols for adenovirus vectors that enable transduction of mammalian cells for regulated expression of several transgenes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Edelstein, M.L. Abedi, M.R. Wixon, J., and Edelstein, R.M. (2004) Gene therapy clinical trials worldwide 1989–2004-an overview. J Gene Me. 6, 597–602.
Tomanin, R. and Scarpa, M. (2004) Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther;. 4, 357–372.
Vandendriessche, T.C. (2002) Clinical gene therapy - first international conference. IDrugs. 5, 209–212.
Everts, M. and Curiel, D.T. (2004) Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther. 4, 337–346.
Glasgow, J.N. Bauerschmitz, G.J. Curiel, D.T., and Hemminki, A. (2004) Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther. 4, 1–14.
Gomez-Manzano, C. Yung, W.K. Alemany, R., and Fueyo, J. (2004) Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology. 63, 418–426.
Liu, M. Acres, B. Balloul, J.M. Bizouarne, N. Paul, S. Slos, P., and Squiban, P. (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA. 101, 14567–14571.
Kamen, A. and Henry, O. (2004) Development and optimization of an adenovirus production process. J Gene Med. 6, 184–192.
McConnell, M.J. and Imperiale, M.J. (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 15, 1022–1033.
Trapnell, B.C. (1993) Quantitative evaluation of gene expression in freshly isolated human respiratory epithelial cells. Am J Physiol. 264, 199–212.
Volpers, C. and Kochanek, S. (2004) Adenoviral vectors for gene transfer and therapy. J Gene Med. 6, 164–171.
Danthinne, X. and Imperiale, M.J. (2000) Production of first generation adenovirus vectors: a review. Gene Ther. 7, 1707–1714.
Russell, W.C. (2000) Update on adenovirus and its vectors. J Gen Virol. 81, 2573–2604.
Lusky, M. Christ, M. Rittner, K. Dieterle, A. Dreyer, D. Mourot, B. Schultz, H. Stoeckel, F. Pavirani, A., and Mehtali, M. (1998) In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol. 72, 2022–2032.
Weber, W. and Fussenegger, M. (2004) Approaches for trigger-inducible viral transgene regulation in gene-based tissue engineering. Curr Opin Biotechnol. 15, 383–391.
Toniatti, C. Bujard, H. Cortese, R., and Ciliberto, G. (2004) Gene therapy progress and prospects: transcription regulatory systems. Gene Ther. 11, 649–657.
Weber, W. Marty, R.R. Keller, B. Rimann, M. Kramer, B.P., and Fussenegger, M. (2002) Versatile macrolide-responsive mammalian expression vectors for multiregulated multigene metabolic engineering. Biotechnol Bioeng. 80, 691–705.
Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 89, 5547–5551.
Gossen, M. Freundlieb, S. Bender, G. Muller, G. Hillen, W. Bujard, H. (1995) Transcriptional activation by tetracyclines in mammalian cells. Science. 268, 1766–1769.
Fussenegger, M. Morris, R.P. Fux, C. Rimann, M. von Stockar, B. Thompson, C.J., and Bailey, J.E. (2000) Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol. 18, 1203–1208.
Weber, W. and Fussenegger, M. (2004) Inducible gene expression in mammalian cells and mice. Methods Mol Biol. 267, 451–66.
Fussenegger, M. Moser, S. Mazur, X., and Bailey, J.E. (1997) Autoregulated multicistronic expression vectors provide one-step cloning of regulated product gene expression in mammalian cells. Biotechnol Prog. 13, 733–740.
Fux, C. Moser, S. Schlatter, S. Rimann, M. Bailey, J.E., and Fussenegger, M. (2001) Streptogramin- and tetracycline-responsive dual regulated expression of p27(Kip1) sense and antisense enables positive and negative growth control of Chinese hamster ovary cells. Nucleic Acids Res. 29, E19.
Kramer, B.P. Viretta, A.U. Daoud-El-Baba, M. Aubel, D. Weber, W., and Fussenegger, M. (2004) An engineered epigenetic transgene switch in mammalian cells. Nat Biotechnol. 22, 867–870.
Moser, S. Rimann, M. Fux, C. Schlatter, S. Bailey, J.E., and Fussenegger, M. (2001) Dual-regulated expression technology: a new era in the adjustment of heterologous gene expression in mammalian cells. J Gene Med. 3, 529–49.
Gonzalez-Nicolini, V. and Fussenegger, M. (2005) A novel binary adenovirus-based dual-regulated expression system for independent transcription control of two different transgenes. J Gene Med. 7, 1573–85.
Fux, C. and Fussenegger, M. (2003) Bidirectional expression units enable streptogramin-adjustable gene expression in mammalian cells. Biotechnol Bioeng. 83, 618–625.
Nyberg-Hoffman, C. Shabram, P. Li, W. Giroux, D., and Aguilar-Cordova, E. (1997) Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med. 3, 808–811.
Dion, L.D. Fang, J., and Garver, R.I. Jr. (1996) Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods. 56, 99–107.
Kelm, J.M. Djonov, V. Hoerstrup, S.P. Guenter, C.I. Ittner, L.M. Greve, F. Hierlemann, A. Sanchez-Bustamante, C.D. Perriard, J.C. Ehler, E., and Fussenegger, M. (2006) Tissue-transplant fusion and vascularization of myocardial microtissues and macrotissues implanted into chicken embryos and rats. Tissue Eng. 12, 2541–53.
Berger, J. Hauber, J. Hauber, R. Geiger, R., and Cullen, B.R. (1988) Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene. 66, 1–10.
Schlatter, S. Rimann, M. Kelm, J., and Fussenegger M. (2002) SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alpha-amylase. Gene. 282, 19–31.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gonzalez-Nicolini, V., Fussenegger, M. (2008). Adenovirus-Mediated Transduction of Auto- and Dual-Regulated Transgene Expression in Mammalian Cells. In: Le Doux, J.M. (eds) Gene Therapy Protocols. Methods in Molecular Biology™, vol 434. Humana Press. https://doi.org/10.1007/978-1-60327-248-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-60327-248-3_14
Publisher Name: Humana Press
Print ISBN: 978-1-60327-247-6
Online ISBN: 978-1-60327-248-3
eBook Packages: Springer Protocols